Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 10 crawled time : 16:20 save search
Female contraceptive market size to grow by USD 5,142.22 million: Personal products industry is the parent market - Technavio
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.64 0.64% 1.6M
|
Health Technology
| Email alert
Add to watchlist
VERU | $1.27 0.0% 2.6M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.48 0.24% 6.8M
|
Health Technology
| Email alert
Add to watchlist
RBGLY | News | $10.59 -2.05% 850K
|
Manufacturing
| Email alert
Add to watchlist
RBGPF | News | $52.06 6.46% 4.8K
|
Consumer Non-Durables
| Email alert
Add to watchlist
contraceptive market
CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against The Gap, Inc.
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
GPS 4 | $20.935 0.89% 4.7M
|
Retail Trade
| Email alert
Add to watchlist
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
| Email alert
Add to watchlist
hemgenix therapy living
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.48 0.24% 6.8M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
imbruvica treatment glow leukemia response plus results study
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
FATE | News | $4.54 -5.02% -5.29% 4M
|
Health Technology
| Email alert
Add to watchlist
meeting t-cell therapeutics therapy
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
ADPT | $2.575 2.59% 2.52% 1.5M
|
Commercial Services
| Email alert
Add to watchlist
clonoseq blood meeting
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
BEAM | $23.54 -2.32% 920K
|
Health Technology
| Email alert
Add to watchlist
disease preclinical therapeutics platform
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
LVTX | $2.99 4.91% 4.68% 110K
|
| Email alert
Add to watchlist
lava-051 meeting trial therapeutics phase 1
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
STRO | $3.73 -1.06% -1.07% 720K
|
Health Technology
| Email alert
Add to watchlist
stro-002 biopharma aml program presentation
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
KURA | News | $18.75 3.08% 830K
|
Health Technology
| Email alert
Add to watchlist
komet-001 meeting trial
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
AEON | $4.235 -10.27% 66K
|
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 380K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
Your saved searches
Save your searches and get alerts when important news are released.